| Ident. | Authors (with country if any) | Title |
|---|
| 000276 |
M. Anne Harris [Canada] ; Joseph K. Tsui [Canada] ; Stephen A. Marion [Canada] ; HUI SHEN [Canada] ; Kay Teschke [Canada] | Association of Parkinson's Disease With Infections and Occupational Exposure to Possible Vectors |
| 000383 |
Christopher Kobylecki [Royaume-Uni] ; Michael P. Hill [Canada] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada] | Synergistic Antidyskinetic Effects of Topiramate and Amantadine in Animal Models of Parkinson's Disease |
| 000488 |
Benjamin Dehay [France] ; Erwan Bezard [France] | New Animal Models of Parkinson's Disease |
| 000558 |
Anne-Sophie Rolland [France] ; Carine Karachi [France] ; Marie-Paule Muriel [France] ; Etienne C. Hirsch [France] ; Chantal Francois [France] | Internal Pallidum and Substantia Nigra Control Different Parts of the Mesopontine Reticular Formation in Primate |
| 000718 |
Martina Wolf [Allemagne] ; Andreas Bruehschwein [Allemagne] ; Carola Sauter-Louis [Allemagne] ; Adrian C. Sewell [Allemagne] ; Andrea Fischer [Allemagne] | An Inherited Episodic Head Tremor Syndrome in Doberman Pinscher Dogs |
| 000731 |
Erwan Bezard [France] ; Serge Przedborski [États-Unis] | A Tale on Animal Models of Parkinson's Disease |
| 000994 |
Hans C. Scholle [Allemagne] ; H. A. Jinnah [États-Unis] ; Dirk Arnold [Allemagne] ; Frank H. W. Biedermann [Allemagne] ; Bernd Faenger [Allemagne] ; Roland Grassme [Allemagne] ; Ellen J. Hess [États-Unis] ; Nikolaus P. Schumann [Allemagne] | Kinematic and Electromyographic Tools for Characterizing Movement Disorders in Mice |
| 000B92 |
Pershia Samadi [Canada] ; Marc Morissette [Canada] ; Daniel Levesque [Canada] ; Thérèse Di Paolo [Canada] | BDNF Levels Are Not Related with Levodopa-Induced Dyskinesias in MPTP Monkeys |
| 000D83 |
Glenda Halliday [Australie] ; Maria Trinidad Herrero [Espagne] ; Karen Murphy [Australie] ; Heather Mccann [Australie] ; Francisco Ros-Bemal [Espagne] ; Carlos Barcia [Espagne] ; Hideo Mori [Japon] ; Francisco J. Blesa [Espagne] ; José A. Obeso [Espagne] | No Lewy Pathology in Monkeys with Over 10 Years of Severe MPTP Parkinsonism |
| 000F02 |
Carine Karachi [France] ; David Grabli [France] ; Nicolas Baup [France] ; Stéphanie Mounayar [France] ; Dominique Tande [France] ; Chantal Francois [France] ; Etienne C. Hirsch [France] | Dysfunction of the Subthalamic Nucleus Induces Behavioral and Movement Disorders in Monkeys |
| 001070 |
Christos Tsironis [Grèce] ; Marios Marselos [Grèce] ; Angelos Evangelou [Grèce] ; Spiridon Konitsiotis [Grèce] | The Course of Dyskinesia Induction by Different Treatment Schedules of Levodopa in Parkinsonian Rats : Is Continuous Dopaminergic Stimulation Necessary? |
| 001146 |
Thomas L. Shirley [États-Unis] ; Lekha M. Rao [États-Unis] ; Ellen J. Hess [États-Unis] ; H. A. Jinnah [États-Unis] | Paroxysmal Dyskinesias in Mice |
| 001204 |
Mitchell F. Brin [États-Unis] ; Cynthia L. Comella [États-Unis] ; Joseph Jankovic [États-Unis] ; Francis Lai [États-Unis] ; Markus Naumann [Allemagne] | Long-Term Treatment with Botulinum Toxin Type A in Cervical Dystonia Has Low Immunogenicity by Mouse Protection Assay |
| 001211 |
Jose L. Lanciego [Espagne] ; Maria C. Rodriguez-Oroz [Espagne] ; Francisco J. Blesa [Espagne] ; Lydia Alvarez-Erviti [Espagne] ; Jorge Guridi [Espagne] ; Pedro Barroso-Chinea [Espagne] ; Yoland Smith [États-Unis] ; Jose A. Obeso [Espagne] | Lesion of the Centromedian Thalamic Nucleus in MPTP-Treated Monkeys |
| 001272 |
Kunal Chaniary [États-Unis] ; Mark Baron [États-Unis] ; Ann Rice [États-Unis] ; Paul Wetzel [États-Unis] ; Steven Shapiro [États-Unis] | Electromyographic Characterization in an Animal Model of Dystonia |
| 001386 |
Brian B. Koo [États-Unis] ; PINGFU FENG [États-Unis] ; Jesse Dostal [États-Unis] ; Kingman P. Strohl [États-Unis] | A-Melanocyte Stimulating Hormone and Adrenocorticotropic Hormone : An Alternative Approach When Thinking About Restless Legs Syndrome? |
| 001452 |
Christopher D. Herzog [États-Unis] ; Biplob Dass [États-Unis] ; James E. Holden [États-Unis] ; James Iii Stansell [États-Unis] ; Mehdi Gasmi [États-Unis] ; Mark H. Tuszynski [États-Unis] ; Raymond T. Bartus [États-Unis] ; Jeffrey H. Kordower [États-Unis] | Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys |
| 001510 |
Anne M. Landau [Canada] ; Edouard Kouassi [Canada] ; Rosmarie Siegrist-Johnstone [Canada] ; Julie Desbarats [Canada] | Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle |
| 001589 |
Nadia Stefanova [Autriche] ; Markus Reindl [Autriche] ; Manuela Neumann [Allemagne] ; Philipp J. Kahle [Allemagne] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Microglial Activation Mediates Neurodegeneration Related to Oligodendroglial α-Synucleinopathy : Implications for Multiple System Atrophy |
| 001614 |
Anthony P. Nicholas [États-Unis] | Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 001650 |
Nadia Stefanova [Autriche] ; Martin Köllensperger [Autriche] ; Monika Hainzer [Autriche] ; Angela Cenci [Suède] ; Werner Poewe [Autriche] ; Gregor Karl Wenning [Autriche] | High dose Levodopa therapy is not toxic in multiple system atrophy: Experimental evidence |
| 001946 |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in Parkinsonian monkeys : Implication of preproenkephalin |
| 001B76 |
Concepcio Marin [Espagne] ; Esther Aguilar [Espagne] ; José A. Obeso [Espagne] | Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats |
| 001C18 |
Gloria E. Meredith [États-Unis] ; UN JUNG KANG [États-Unis] | Behavioral models of Parkinson's disease in rodents : A new look at an old problem |
| 001D91 |
Dirk Dressler [Allemagne] ; M. Lange [Allemagne] ; Hans Bigalke [Allemagne] | Mouse diaphragm assay for detection of antibodies against botulinum toxin type B |
| 001E69 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada] | Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys |
| 001E82 |
Jason D. Dapper [États-Unis] ; Monica J. Justice [États-Unis] | Defining the breakpoints of the Quakingviable mouse mutation reveals a duplication from a Parkin intron |
| 001F37 |
Gwenaelle Fillon [Allemagne] ; Philipp J. Kahle [Allemagne] | Alpha-synuclein transgenic mice : Relevance to multiple system atrophy |
| 002011 |
H. A. Jinnah [États-Unis] ; Ellen J. Hess [États-Unis] ; Mark S. Ledoux [États-Unis] ; Nutan Sharma [États-Unis] ; Mark G. Baxter [Royaume-Uni] ; Mahlon R. Delong [États-Unis] | Rodent models for dystonia research : Characteristics, evaluation, and utility |
| 002023 |
Tomas Gonzalez-Hernandez [Espagne] ; Pedro Barroso-Chinea [Espagne] ; Manuel Rodriguez [Espagne] | Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat |
| 002120 |
Paul J. Lockhart [États-Unis] ; Casey A. O'Farrell [États-Unis] ; Matthew J. Farrer [États-Unis] | It's a double knock-out! The Quaking mouse is a spontaneous deletion of Parkin and Parkin co-regulated gene (PACRG) |
| 002312 |
Anna Mura [Suisse] ; Joram Feldon [Suisse] | Spatial learning in rats is impaired after degeneration of the nigrostriatal dopaminergic system |
| 002391 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
| 002405 |
Michael Orth [Royaume-Uni] ; Sarah J. Tabrizi [Royaume-Uni] | Models of Parkinson's disease |
| 002450 |
Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease |
| 002457 |
Jay S. Schneider [États-Unis] ; Timothy V. Wade [États-Unis] | Experimental parkinsonism is associated with increased pallidal GAD gene expression and is reversed by site-directed antisense gene therapy |
| 002465 |
Kathy Steece-Collier [États-Unis] ; Timothy J. Collier [États-Unis] ; Paul D. Danielson [États-Unis] ; Roger Kurlan [États-Unis] ; David M. Yurek [États-Unis] ; John R. Jr Sladek [États-Unis] | Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in Parkinsonian rats |
| 002471 |
Gregorio Segovia [Royaume-Uni, Espagne] ; Francisco Mora [Espagne] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease |
| 002472 |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson ; Matthew J. Hansard ; Eleni Maratos ; Peter Jenner | Effect of pulsatile administration of Levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure |
| 002495 |
Daphna Joel [Israël] ; Liat Ayalon [Israël] ; Ricardo Tarrasch [Israël] ; Ina Weinei [Israël] | Deficits induced by quinolinic acid lesion to the striatum in a position discrimination and reversal task are ameliorated by permanent and temporary lesion to the globus pallidus: A potential novel treatment in a rat model of Huntington's disease |
| 002514 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
| 002556 |
Ergun Y. Uc [États-Unis] ; Gerald A. Dienel [États-Unis] ; Nancy F. Cruz [États-Unis] ; Sami I. Harik [États-Unis] | β-Adrenergics enhance brain extraction of levodopa |
| 002582 |
Ronald K. B. Pearce [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jorgen Scheel-Krüger [Danemark] ; Peter Jenner [Royaume-Uni] | The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets |
| 002583 |
Paul J. May [États-Unis] ; Robert G. Baker [États-Unis] ; BINGZHONG CHEN [États-Unis] | The eyelid levator muscle: Servant of two masters |
| 002585 |
Louis C. Tan [États-Unis] ; Peter H. Protell [États-Unis] ; J. William Langston [États-Unis] ; Daniel M. Togasaki [États-Unis] | The Hyperkinetic Abnormal Movements Scale: A tool for measuring levodopa-induced Abnormal Movements in squirrel monkeys |
| 002590 |
Rebecka Klintenberg [Suède] ; Lars Gunne [Suède] ; Per E. Andren [Suède] | Tardive dyskinesia model in the common marmoset |
| 002601 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni] | Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
| 002626 |
Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation |
| 002662 |
Alfredo Berardelli [Italie] ; Antonio Curra [Italie] | Pathophysiology and treatment of cranial dystonia |
| 002673 |
J. A. Biittner-Ennever [Allemagne] ; A. K. E. Horn [Allemagne] | Oculomotor system: A dual innervation of the eye muscles from the abducens, trochlear, and oculomotor nuclei |
| 002685 |
Igor A. Ilinsky [États-Unis] ; Kristy Kultas-Ilinsky [États-Unis] | Motor thalamic circuits in primates with emphasis on the area targeted in treatment of movement disorders |
| 002710 |
Marie-Paule Muriel [France] ; Gaël Orieux [France] ; Etienne C. Hirsch [France] | Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in Parkinsonian rats |
| 002834 |
Joanne E. Nash [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Characterisation of striatal NMDA receptors involved in the generation of Parkinsonian symptoms: Intrastriatal microinjection studies in the 6-OHDA-lesioned rat |
| 002840 |
Dipankar Nandi [Royaume-Uni] ; Tipu Z. Aziz [Royaume-Uni] ; XUGUANG LIU [Royaume-Uni] ; John F. Stein [Royaume-Uni] | Brainstem motor loops in the control of movement |
| 002841 |
Peter J. Healy [Australie] ; Kerrie D. Pierce [Australie] ; Julie A. Dennis [Australie] ; Peter A. Windsor [Australie] ; Peter R. Schofield [Australie] | Bovine myoclonus: Model of human hyperekplexia (Startle disease) |
| 002851 |
Mikko Kuoppam Ki [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Michael Jackson [Royaume-Uni] ; Lance Smith [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa |
| 002864 |
Frans Vanderwerf [Pays-Bas] ; Catherine Buisseret-Delmas [France] ; Pierre Buisseret [France] | Afferent innervation of eyelids and their connections to the superior colliculus |
| 002896 |
Adrian Handforth [États-Unis] ; Scott E. Krahl [États-Unis] | Suppression of harmaline-induced tremor in rats by vagus nerve stimulation |
| 002911 |
Oum-Kaltoum Hassani [France] ; Mireille Mouroux [France] ; Georg Andrees Bohme [France] ; Jean-Marie Stutzmann [France] ; Jean Feger [France] | Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain |
| 002916 |
G. M. Petzinger [États-Unis] ; M. Quik [États-Unis] ; E. Ivashina [États-Unis] ; M. W. Jakowec [États-Unis] ; M. Jakubiak [États-Unis] ; D. Di Monte [États-Unis] ; J. W. Langston [États-Unis] | Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate |
| 002931 |
Jon H. Falkenberg [États-Unis] ; Paul A. Laizzo [États-Unis] ; Linda K. Mcloon [États-Unis] | Physiological assessment of muscle strength in vitro after direct injection of Doxorubicin into rabbit sternocleidomastoid muscle |
| 002944 |
R. E. Yee [États-Unis] ; I. Irwin [États-Unis] ; C. Milonas [États-Unis] ; D. B. Stout [États-Unis] ; S-C. Huang [États-Unis] ; K. Shoghi-Jadid [États-Unis] ; N. Satyamurthy [États-Unis] ; L. E. Delanney [États-Unis] ; D. M. Togasaki [États-Unis] ; K. F. Farahani [États-Unis] ; K. Delfani [États-Unis] ; A. M. Janson [États-Unis] ; M. E. Phelps [États-Unis] ; J. W. Langston [États-Unis] ; J. R. Barrio [États-Unis] | Novel observations with FDOPA-PET imaging after early nigrostriatal damage |
| 002952 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan |
| 002969 |
L. Munro-Davies [Royaume-Uni] ; J. Winter [Royaume-Uni] ; T. Z. Aziz [Royaume-Uni] ; J. Stein [Royaume-Uni] | Kainate acid lesions of the pedunculopontine region in the normal behaving primate |
| 002A36 |
Krishna P. Datla [Royaume-Uni] ; Stavia B. Blunt [Royaume-Uni] ; David T. Dexter [Royaume-Uni] | Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostriatal lesions |
| 002A41 |
Hélène Turmel [France] ; Andreas Hartmann [France] ; Karine Parain [France] ; Aicha Doubou [France] ; Anu Srinivasan [États-Unis] ; Yves Agid [France] ; Etienne C. Hirsch [France] | Caspase-3 activation in 1 -methyl-4-phenyl- 1, 2,3,6-tetrahydropyridine (MPTP)-treated mice |
| 002A60 |
Eleni C. Maratos [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus) |
| 002A75 |
| Abstracts of the sixth international congress of Parkinson's disease and movement disorders, Barcelona, Spain, June 11-15, 2000 |
| 002A90 |
I. Ghorayeb [France] ; P. O. Fernagut [France] ; I. Aubert [France] ; E. Bezard [France] ; Werner Poewe [Autriche] ; G. K. Wenning [Autriche] ; F. Tison [France] | Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration |
| 002B26 |
D. A. Di Monte [États-Unis] ; A. Mccormack [États-Unis, Suède] ; G. Petzinger [États-Unis] ; A. M. Janson [États-Unis, Suède] ; M. Quik [États-Unis] ; W. J. Langston [États-Unis] | Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model |
| 002B40 |
C. G. Goetz [États-Unis] ; T. Q. Vu ; P. M. Carvey ; S. Leurgans | Posthypoxic myoclonus in the rat : Natural history, stability, and serotonergic influences |
| 002B85 |
R. R. Matsumoto [États-Unis] ; D. D. Truong [États-Unis] ; K. D. Nguyen [États-Unis] ; A. T. Dang [États-Unis] ; T. T. Hoang [États-Unis] ; P. Q. Vo [États-Unis] ; P. Sandroni [États-Unis] | Involvement of GABAA receptors in myoclonus |
| 002C07 |
Manuel Rodriguez [Espagne] ; Patricio Abdala [Espagne] ; José A. Obeso [Espagne] | Excitatory responses in the 'direct' striatonigral pathway : Effect of nigrostriatal lesion |
| 002C12 |
R. G. Geocadin [États-Unis] ; J. Muthuswamy [États-Unis] ; D. L. Sherman [États-Unis] ; N. V. Thakor [États-Unis] ; D. F. Hanley [États-Unis] | Early electrophysiological and histologic changes after global Cerebral ischemia in rats |
| 002C25 |
S. Palfi [États-Unis] ; L. Leventhal [États-Unis] ; C. G. Goetz [États-Unis] ; P. Hantraye [France] ; B.-Z. Roitberg [États-Unis] ; J. Sramek [États-Unis] ; M. Emborg [États-Unis] ; J. H. Kordower [États-Unis] | Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys |
| 002C35 |
W. G. Ondo [États-Unis] ; YI HE [États-Unis] ; S. Rajasekaran [États-Unis] ; W.-D. Le [États-Unis] | Clinical correlates of 6-hydroxydopamine injections into all dopaminergic neurons in rats : A possible model for restless legs syndrome? |
| 002C43 |
H. A. Jinnah [États-Unis] ; J. P. Sepkuty [États-Unis] ; T. Ho [États-Unis] ; S. Yitta [États-Unis] ; T. Drew [États-Unis] ; J. D. Rothstein [États-Unis] ; E. J. Hess [États-Unis] | Calcium channel agonists and dystonia in the mouse |
| 002C60 |
D. D. Truong [États-Unis] ; A. Kanthasamy [États-Unis] ; BANG NGUYEN [États-Unis] ; R. Matsumoto [États-Unis] ; P. Schwartz [États-Unis] | Animal models of posthypoxic myoclonus : I. Development and validation |
| 002C61 |
B. Q. Nguyen [États-Unis] ; A. G. Kanthasamy [États-Unis] ; D. D. Truong [États-Unis] | Animal models of myoclonus : An overview |
| 002C62 |
A. G. Kanthasamy [États-Unis] ; B. Q. Nguyen ; D. D. Truong | Animal model of posthypoxic myoclonus : II. Neurochemical, pathologic, and pharmacologic characterization |
| 002D01 |
B. Henry [Royaume-Uni] ; S. H. Fox [Royaume-Uni] ; D. Peggs [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-Parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease |
| 002D35 |
J. M. Brotchie [Royaume-Uni] ; S. H. Fox [Royaume-Uni] | Quantitative assessment of dyskinesias in subhuman primates |
| 002D69 |
F. Cardozo-Pelaez [États-Unis] ; SHIJIE SONG ; A. Parthasarathy ; C. Hazzi ; K. Naidu ; J. Sanchez-Ramos | Oxidative DNA damage in the aging mouse brain |
| 002D79 |
K. S. Topp [États-Unis] ; N. N. Byl [États-Unis] | Movement dysfunction following repetitive hand opening and closing : Anatomical analysis in owl monkeys |
| 002D97 |
R. K. B. Pearce [Royaume-Uni] | L-dopa and dyskinesias in normal monkeys |
| 002E65 |
E. Grünblatt [Israël] ; S. Mandel [Israël] ; T. Berkuzki [Israël] ; M. B. H. Youdim [Israël] | Apomorphine protects against MPTP-induced neurotoxicity in mice |
| 002E68 |
H. Wilms [Allemagne] ; J. Sievers [Allemagne] ; G. Deuschl [Allemagne] | Animal models of tremor |
| 002E89 |
| Tremor: basic mechanisms and clinical aspects |
| 002E90 |
A. Richter [Allemagne] ; J. M. Brotchie [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; W. Löscher [Allemagne] | [3H]-2-Deoxyglucose uptake study in mutant dystonic hamsters : Abnormalities in discrete brain regions of the motor system |
| 002F35 |
M. Gernert [Allemagne] ; A. Richter [Allemagne] ; C. Rundfeldt [Allemagne] ; W. Löscher [Allemagne] | Quantitative EEG analysis of depth electrode recordings fron several brain regions of mutant hamsters with paroxysmal dystonia discloses frequency changes in the basal ganglia |
| 002F41 |
P. Hagell [Suède] ; P. Odin [Allemagne] ; E. Vinge [Suède] | Pregnancy in Parkinson's disease : A review of the literature and a case report |
| 002F42 |
UN JUNG KANG [États-Unis] | Potential of gene therapy for Parkinson's disease : Neurobiologic issues and new developments in gene transfer methodologies |
| 002F49 |
H. Bergman [Israël] ; A. Raz [Israël] ; A. Feingold [Israël] ; A. Nini [Israël] ; I. Nelken [Israël] ; D. Hansel [France] ; H. Ben-Pazi [Israël] ; A. Reches [Israël] | Physiology of MPTP tremor |
| 002F79 |
S. Przedborski [États-Unis] ; V. Jackson-Lewis [États-Unis] | Mechanisms of MPTP toxicity |
| 002F86 |
N. R. Hughes [Royaume-Uni] ; A. T. Mcknight [Royaume-Uni] ; G. N. Woodruff [Royaume-Uni] ; M. P. Hill [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism |
| 003006 |
O. Bandmann [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; N. W. Wood [Royaume-Uni] | Genetic aspects of Parkinson's disease |
| 003038 |
A. P. Payne [Royaume-Uni] ; R. G. Sutcliffe [Royaume-Uni] ; J. M. Campbell [Royaume-Uni] ; G. Favor [Royaume-Uni] ; D. Russell [Royaume-Uni] ; N. K. Bennett [Royaume-Uni] ; D. J. Clarke [Royaume-Uni] ; R. Branton [Royaume-Uni] ; R. W. Davies [Royaume-Uni] ; E. Simpson [Royaume-Uni] ; C. Tsang [Royaume-Uni] ; R. H. Baxendale [Royaume-Uni] | Disordered locomotion in the AS/AGU mutant rat and the effects of L-dopa or fetal midbrain grafts |
| 003083 |
R. J. Elble [États-Unis] | Animal models of action tremor |
| 003085 |
P. J. Blanchet [États-Unis] ; S. Konitsiotis [États-Unis] ; T. N. Chase [États-Unis] | Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys |
| 003095 |
P. A. Lapchak [États-Unis] | A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease |
| 003128 |
L. Rioux [États-Unis] ; P. A. Frohna [États-Unis] ; J. N. Joyce [États-Unis] ; J. S. Schneider [États-Unis] | The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys |
| 003130 |
M. Jaber [États-Unis] ; S. Jones ; B. Giros ; M. G. Caron | The dopamine transporter : A crucial component regulating dopamine transmission |
| 003176 |
E. S. Simon [États-Unis] | Phenotypic heterogeneity and disease course in three murine strains with mutations in genes encoding for α1 and β glycine receptor subunits |
| 003198 |
G. Dziewczapolski [Argentine] ; L. B. Menalled [Argentine] ; M. T. Savino [Argentine] ; M. Mora [Argentine] ; F. J. E. Stefano [Argentine] ; O. Gershanik [Argentine] | Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the "super-off" phenomenon |
| 003205 |
I. Ziv [Israël] ; R. Zilkha-Falb [Israël] ; D. Offen [Israël] ; A. Shirvan [Israël] ; A. Barzilai [Israël] ; E. Melamed [Israël] | Levodopa induces apoptosis in cultured neuronal cells : A possible accelerator of nigrostriatal degeneration in Parkinson's disease? |
| 003232 |
L. A. Smith [Royaume-Uni] ; A. Gordin [Finlande] ; P. Jenner [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets |
| 003290 |
J. Wissel [Autriche] ; B. Harlizuis [Allemagne] ; A. Richter [Allemagne] ; W. Löscher [Allemagne] ; L. Schelosky [Allemagne] ; U. Scholz [Allemagne] ; Werner Poewe [Autriche] | A new tremor mutant in the Pietrain pig : An animal model of orthostatic tremor? Clinical and neurophysiological observations |
| 003324 |
G. K. Wenning [Royaume-Uni] ; R. Granata [Italie] ; P. M. Laboyrie [Royaume-Uni] ; N. P. Quinn [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration |
| 003339 |
B.-Y. Zeng [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | Partial reversal of increased preproenkephalin messenger ribonucleic acid (mRNA) and decreased preprotachylikin mRNA by foetal dopamine cells in unilateral 6-hydroxydopamine-lesioned rat striatum parallels functional recovery |
| 003379 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
| 003383 |
J. A. Vilensky [États-Unis] ; S. Gilman ; R. J. Morecraft | DC60 : An example of one of the 450 cases that compose the Denny-Brown collection of primate lesion material |
| 003413 |
L. Smith [Royaume-Uni] ; M. De Salvia [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets |
| 003415 |
A. Benazzouz [France] ; T. Boraud [France] ; J. Feger [France] ; P. Burbaud [France] ; B. Bioulac [France] ; C. Gross [France] | Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates : A comparison with L-dopa treatment |
| 003494 |
W. Löscher [Allemagne] ; T. Blanke [Allemagne] ; A. Richter [Allemagne] ; H.-O. Hoppen | Gonadal sex hormones and dystonia : experimental studies in genetically dystonic hamsters |
| 003502 |
R. R. Matsumoto [États-Unis] ; M. J. Hussong ; D. D. Truong | Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus |
| 003512 |
R. K. B. Pearce [Royaume-Uni] ; M. Jackson [Royaume-Uni] ; L. Smith [Royaume-Uni] ; P. Jenner ; C. D. Marsden | Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus) |
| 003528 |
S. Przedborski [États-Unis] ; V. Jackson-Lewis ; S. Fahn | Antiparkinsonian therapies and brain mitochondrial complex I activity |
| 003564 |
R. J. Vermeulen [Pays-Bas] ; B. Drukarch [Pays-Bas] ; M. C. R. Sahadat ; C. Goosen ; E. C. Wolters [Pays-Bas] ; J. C. Stoof [Pays-Bas] | The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys |
| 003592 |
D. D. Truong [États-Unis] ; R. R. Matsumoto [États-Unis] ; P. H. Schwartz [États-Unis] ; M. J. Hussong [États-Unis] ; C. G. Wasterlain | Novel rat cardiac arrest model of posthypoxic myoclonus |
| 003595 |
J. D. Belluzzi [États-Unis] ; E. F. Domino ; J. M. May ; K. S. Bankiewicz ; D. A. Mcafee | N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease |
| 003610 |
G. E. Borodic [États-Unis] ; R. Ferrante ; L. Bruce Pearce ; K. Smith [États-Unis] | Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections |
| 003633 |
S. Rose [Royaume-Uni] ; P. Jenner ; C. D. Marsden | Chronic administration does not alter the accumulation of L-dopa into muscle |
| 003669 |
A. J. Stoessl [Canada] ; E. Polanski ; H. Frydryszak | The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia |
| 003671 |
I. Rektor [France] ; M. Svejdova ; C. Silva-Barrat ; C. Menini | The cholinergic system-dependent myoclonus of the baboon Papio papio is a reticular reflex myoclonus |
| 003676 |
S. B. Blunt [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine |
| 003685 |
C. A. Hubbard [États-Unis] ; J. M. Trugman | Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists |
| 003708 |
K. T. Finnegan [États-Unis] | Neurotoxins and monoamine oxidase inhibition: new aspects |
| 003733 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
| 003759 |
M. Guttman [Canada] ; G. Leger ; A. Reches ; A. Evans ; H. Kuwabara ; J. M. Cedarbaum ; A. Gjedde | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa |
| 003777 |
J. D. Wirtschafter [États-Unis] ; D. P. Slovut ; L. Stordal ; J. Valentino ; L. K. Mcloon | Severe but temporary injury to rabbit orbicularis oculi muscle using dihematoporphyrin ether and laser photochemomyectomy |
| 003779 |
I. J. Mitchell [Royaume-Uni] ; A. R. Crossman ; U. Liminga ; P. Andren ; L. M. Gunne | Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the cebus monkey |
| 003819 |
B. Gomez-Mancilla [Canada] ; J.-F. Latulippe ; R. Boucher ; P. J. Bedard | Effect of ethosuximide on rest tremor in the MPTP monkey model |
| 003821 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
| 003838 |
| |
| 003864 |
R. Kurlan [États-Unis] ; M. H. Kim ; D. M. Gash | Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys : assessment with a new rating scale for monkey parkinsonism |
| 003867 |
S. Brailowsky | Myoclonus in Papio papio |
| 003870 |
T. Z. Aziz [Royaume-Uni] ; D. Peggs ; M. A. Sambrook ; A. R. Crossman | Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonims in the primate |
| 003871 |
F. Dagani [Italie] ; R. Ferrari ; J. I. Anderson ; T. N. Chase | L-Dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria |
| 003875 |
G. Pezzoli [Italie] ; A. Zecchinelli ; S. Ricciardi ; R. E. Burke ; S. Fahn ; G. Scarlato ; A. Carenzi | Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats |
| 003903 |
J. M. Brotchie ; I. J. Mitchell ; M. A. Sambrook ; A. R. Crossman | Alleviation of Parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate |
| 003922 |
N. M. J. Rupniak ; S. J. Tye ; M. J. Steventon ; S. Boyce ; S. D. Iversen | Spontaneous orofacial dyskinesias in a captive cynomolgus monkey : implications for tardive dyskinesia |
| 003930 |
K. D. Sethi ; A. Hitri ; B. I. Diamond | Phenytoin potentiation of neuroleptic-induced dyskinesias |
| 003935 |
U. Wahnschaffe ; G. Fredow ; P. Heintz ; W. Loêscher | Neuropathological studies in a mutant hamster model of paroxysmal dystonia |
| 003937 |
I. J. Mitchell ; R. Luquin ; S. Boyce ; C. E. Clarke ; R. G. Robertson ; M. A. Sambrook ; A. R. Crossman | Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia |
| 003943 |
S. Boyce ; C. E. Clarke ; R. Luquin ; D. Peggs ; R. G. Robertson ; I. J. Mitchell ; M. A. Sambrook ; A. R. Crossman | Induction of chorea and dystonia in parkinsonian primates |
| 003984 |
W. Löscher ; J. E. Jr Fisher ; D. Schmidt ; G. Fredow ; D. Hönack ; W. B. Iturrian | The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia? |
| 003985 |
W. R. G. Gibb ; M. Terruli ; Andrew Lees (neurologue) [Royaume-Uni] ; P. Jenner ; C. D. Marsden | The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 003996 |
D. T. Dexter ; P. Jenner ; C. D. Marsden | Oxyferriscarbone elevates the total iron content of blood but not brain |
| 003A18 |
J. A. Temlett ; N. P. Quinn ; P. G. Jenner ; C. D. Marsden ; E. Pourcher ; A.-M. Bonnet ; Y. Acid ; R. Markstein ; X. Lataste | Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease |
| 003A30 |
S. Rose ; P. Jenner ; C. D. Marsden | The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats |
| 003A33 |
A. B. Scott ; D. Suzuki | Systemic toxicity of botulinum toxin by intramuscular injection in the monkey |
| 003A47 |
D. Dung Truong ; J. Garcia De Yebenes ; G. Pezzoli ; V. Jackson-Lewis ; S. Fahn | Glycine involvement in DDT-induced myoclonus |
| 003A74 |
W. Koller ; G. Herbster ; J. Gordon | PHNO, a novel dopamine agonist, in animal models of parkinsonism |
| 003A90 |
J. G. De Yebenes ; S. Fahn ; S. Lovelle ; V. Jackson-Lewis ; P. Jorge ; M. A. Mena ; J. Reiriz ; J. C. Bustos ; C. Magarinos ; A. Martinez | Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease |
| 003A97 |
N. Nomoto ; S. Stahl ; P. Jenner ; C. D. Marsden | Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset |
